Opko Health (XCY) Stock Price & Analysis
XCY Stock Chart & Stats
- Day’s Range
- EUR 1.44 - EUR 1.44
- 52-Week Range
- EUR 0.90 - EUR 1.49
- Previous Close
- EUR 1.43
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 1.11B
- Enterprise Value
- EUR 1.23B
- Total Cash (Recent Filing)
- EUR 300.76M
- Total Debt (Recent Filing)
- EUR 392.26M
- Price to Earnings (P/E)
- ―
- Beta
- 0.77
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- -0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Pharmaceutical Revenue Growth
Strong pharmaceutical growth indicates improving demand, commercial execution, and product contribution within OPKO’s higher-value business. If international volumes and RAYALDEE economics remain favorable, this segment can provide a more durable growth engine and help offset pressure in diagnostics.
Pipeline And Strategic Partnerships
A broad clinical pipeline and collaborations with well-resourced partners diversify OPKO’s development opportunities and provide potential access to external funding, milestones, and royalties. Continued program advancement could strengthen the company’s long-term product portfolio beyond current commercial revenue.
Improved Revenue Outlook And Liquidity
Higher full-year revenue guidance, combined with more than $300 million of reported cash, gives OPKO greater capacity to fund research, commercialization, and operations. This financial flexibility supports execution over the next several quarters while the company develops its pipeline and reshapes its portfolio.
Bears Say
Persistent Losses And Weak Margins
OPKO’s revenue rebound has not yet translated into sustainable profitability, with materially negative operating and net margins. Continued losses reduce internally generated capital, make the business more dependent on financing or asset proceeds, and leave earnings power vulnerable if growth or reimbursement progress slows.
Heavy Cash Burn
Substantial negative operating and free cash flow remains a fundamental constraint despite the company’s cash balance. Persistent burn can consume liquidity, limit investment flexibility, and increase reliance on financing, royalty proceeds, or other strategic transactions unless operating performance improves.
Diagnostics Portfolio Contraction
Selling major laboratory testing assets and 4Kscore materially reshapes OPKO’s diagnostics platform and can reduce the recurring revenue base tied to those operations. The transaction may improve liquidity, but it also increases reliance on pharmaceuticals, partnerships, and the remaining diagnostic activities.
Opko Health News
XCY FAQ
What was Opko Health’s price range in the past 12 months?
What is Opko Health’s market cap?
When is Opko Health’s upcoming earnings report date?
How were Opko Health’s earnings last quarter?
Is Opko Health overvalued?
Does Opko Health pay dividends?
What is Opko Health’s EPS estimate?
How many shares outstanding does Opko Health have?
What happened to Opko Health’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Opko Health?
What is the TipRanks Smart Score and how is it calculated?
Opko Health Stock Smart Score
Company Description
Opko Health
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Phillip Frost
- Employees
- 2,275
- Website
- www.opko.com
- Address
- 4400 Biscayne Boulevard, Miami, FL, 33137, US
Opko Health (XCY) Earnings & Revenues
XCY Earnings Call
Earnings Call SentimentPositive
The call conveyed materially positive operational and financial momentum: substantial pipeline progress across ModeX and OPKO biologics, significant revenue growth in the Pharmaceutical segment, a stronger cash position (> $300M), improved consolidated results (much smaller net loss) and upgraded full-year revenue guidance. However, the company faces near-term headwinds including a year-over-year decline in diagnostics revenue tied to prior divestitures, elevated and persistent operating and R&D expenses, timing/reimbursement uncertainty for 4Kscore expansion, and clinical data/enrollment timing risks. Overall, the positive items (cash runway, pipeline advances, large revenue inflection items and much improved profitability metrics) outweigh the lowlights, but several execution and timing risks warrant monitoring.
View all DE:XCY earnings summariesXCY Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 4 | 4 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 11 | 0 | 1 |
